[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatitis-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatitis-chronic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,81,108,134,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100572186","phase-2-pioglitazone-versus-empagliflozin-for-chronic-pancreatitisrecurrent-acute-pancreatitisacute-pancreatitis-associated-diabetes-mellitus-100572186",false,"NCT06729996","Pioglitazone Versus Empagliflozin for Chronic Pancreatitis\u002FRecurrent Acute Pancreatitis\u002FAcute Pancreatitis Associated Diabetes Mellitus","Randomized, Parallel Group, Dose Escalation Trial of Pioglitazone Versus Empagliflozin for Chronic Pancreatitis\u002FRecurrent Acute Pancreatitis\u002FAcute Pancreatitis Associated Diabetes Mellitus: The PEP-DM Trial","PEP-DM","Inclusion Criteria:\n\n1. Age ≥18-80 years at the time of enrollment.\n2. RAP or CP with DM diagnosed before or after CP diagnosis (Confirmed CP on imaging or RAP based on PROCEED study criteria, or acute pancreatitis followed by diabetes (AP-DM) and confirmed DM as per ADA criteria or clinically diagnosed with DM and on antihyperglycemic therapy)\n3. Able to provide written informed consent and participate in longitudinal follow-up\n4. A Stable retinal exam within 1 year prior to enrollment unless new onset diabetes was diagnosed within 6 months prior to study enrollment. If an eye exam within the past year is not available but the most recent exam is stable, a standard of care eye exam needs to be scheduled during the study period.\n5. HbA1c level 6.5-10.5% at screening visit.\n6. Current ongoing treatment with metformin and\u002For insulin and other antihyperglycemic medications will be accepted at screening. Patients will be willing to safely withdraw one or more study medication or mealtime insulin under the supervision of the study team by the time of screening. The patients clinical team will be informed promptly. Patients not on any antihyperglycemic medications are also eligible.\n\n   a. If on a GLP-1 medication (e.g., semaglutide \\[Ozempic, Wegovy, Rybelsus\\], liraglutide, dulaglutide, exenatide, tirzepatide, etc.), the patient must be on a stable dose for at least 3 months prior to enrollment, with stable weight status at the time of enrollment and the GLP-1 dose cannot be escalated during the study period.\n7. Willing to perform blood glucose and ketone testing on study provided meters as per study protocol.\n\nExclusion Criteria:\n\n1. Inability to take PIO or EMPA due to prior hypersensitivity or allergic reaction or current use of medications with potential for drug-drug interactions (Pioglitazone: Drug information - UpToDate, Empagliflozin: Drug information - UpToDate)\n2. Patients on PIO or EMPA at the time of screening\n3. Diagnosed with Type 1 Diabetes\n4. Pregnancy or lactation in women (positive urine pregnancy test at screening will lead to exclusion)\n5. History of bleeding disorders (e.g., Hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), von Willebrand disease, platelet disorders etc)\n6. Presence of hepatic impairment, ALT \\>3 x ULN with no etiology known at the time of enrollment or any evidence of acute\u002Fchronic liver disease\n7. Ongoing treatment for any malignancy requiring systemic treatment (non-melanoma skin cancers treated in dermatologists' office would be acceptable)\n8. Presence of osteoporosis without definitive treatment according to PI discretion.\n9. Recent inflammatory illness within the 30 days preceding enrollment (e.g.: URTI, episode of AP, etc)\n10. History of heart failure classified by NYHA as Class III or greater\n11. History of kidney dysfunction classified by an eGFR of \\\u003C30 mL\u002Fmin\u002Fmin\n12. Participation in any clinical trial within 30 days before screening for an approved or non-approved investigational medical product.\n13. Active alcohol dependence or chemical dependence including tobacco based on investigator discretion\n14. On a ketogenic diet\n15. Autoimmune pancreatitis, obstructive pancreatitis, and prior surgery of pancreas (Whipple procedure, total pancreatectomy, and distal pancreatectomy)\n16. Any condition which could jeopardize participant safety as per investigator opinion, (hemolytic anemia limiting A1c reliability, any evidence of fluid overload, presence of Congestive heart failure etc).\n17. Recent DKA or signs of decompensated diabetes in last 6 months or increased β hydroxybutyrate levels (\\>0.4 mmol\u002FL) at screening.","ALL","18 Years","80 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The purpose of this study is to evaluate efficacy of pioglitazone (PIO) versus empagliflozin (EMPA) to improve glycemic control in people with Chronic Pancreatitis (CP) or Recurrent Acute Pancreatitis (RAP) or Acute Pancreatitis (AP) associated with Diabetes Mellitus (DM). To evaluate mixed meal response in PIO versus EMPA group to better understand physiology of both therapies in CP-DM.",[28,29,30],"Pancreatitis, Chronic","Pancreatitis, Acute","Diabetes Mellitus",[32,33,34,35,36],"pancreatitis","diabetes","diabetes mellitus","empagliflozin","pioglitazone","RECRUITING","2026-07-27",{"date":40,"type":41},"2026-07-29","ACTUAL",{"date":43,"type":41},"2025-05-29",{"date":45,"type":22},"2027-05-31",{"name":47,"class":48},"Mayo Clinic","OTHER",3,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100645922","phase-3-comparative-study-to-evaluate-microbial-versus-porcine-pancreatic-enzyme-therapy-in-chronic-pancreatitis-100645922","NCT07697352","Comparative Study to Evaluate Microbial Versus Porcine Pancreatic Enzyme Therapy in Chronic Pancreatitis","A Randomised, Double-Blind, Non-Inferiority Trial Comparing Microbial and Porcine Pancreatic Enzyme Replacement Therapy in Chronic Pancreatitis","NP-PERT","Inclusion Criteria:\n\n* CP fulfilling the M-ANNHEIM criteria 11 with documented PEI (defined as fecal elastase \\\u003C100 µg\u002Fg stool on the background of morphological changes of CP).\n* Willingness to undergo a 2-week wash-out period without pancreatic enzyme therapy before enrolment.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Major psychiatric illness impairing study participation.\n* Systemic illness affecting digestion or study outcomes.\n* Any condition deemed unsuitable for study participation by the investigator.\n* Concurrent acute exacerbation of the CP at the time of screening.",{"count":59,"type":22},134,[61],"PHASE3","Background: Chronic pancreatitis (CP) is a progressive inflammatory disorder causing irreversible pancreatic damage, eventually resulting in pancreatic exocrine insufficiency (PEI). This may lead to malabsorption, malnutrition, weight loss, and impaired quality of life. Pancreatic enzyme replacement therapy (PERT) is the standard treatment for PEI and is predominantly derived from porcine sources. However, religious, ethical, dietary, and supply-related concerns highlight the need for effective non-porcine alternatives. Microbial (fungal)-based pancreatic enzymes have shown promising safety and efficacy in preliminary studies, but evidence in CP remains limited.\n\nObjective: To compare the efficacy and safety of non-porcine microbial (fungal)-based pancreatin with standard porcine-based pancreatin in patients with PEI secondary to CP.\n\nMethods: This investigator-initiated, randomized, double-blind, single-center, non-inferiority trial will enroll 134 adults with CP-associated PEI (defined as having a fecal elastase \\\u003C100 µg\u002Fg). After a two-week washout period, participants will be randomized 1:1 to receive either microbial-based or porcine-based pancreatin for 12 weeks. The primary outcome is the change from baseline in the Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) score at 12 weeks. Secondary outcomes include nutritional status, anthropometric measures, gastrointestinal symptoms, pain scores, stool consistency, glycaemic parameters, laboratory markers, and quality of life.\n\nDiscussion: This study aims to evaluate whether microbial-based pancreatin is non-inferior to porcine-based therapy and may provide a culturally acceptable and sustainable alternative for managing CP-related PEI.",[28,64],"Exocrine Pancreatic Insufficiency (EPI)",[66,67,68,69,70],"chronic pancreatitis","exocrine pancreatic insufficiency","Pancreatic enzyme replacement therapy","porcine pancreatic enzyme","microbial (fungal) pancreatic enzyme","NOT_YET_RECRUITING","2026-07-05",{"date":74,"type":41},"2026-07-13",{"date":76,"type":22},"2026-08",{"date":78,"type":22},"2027-09",{"name":80,"class":48},"Asian Institute of Gastroenterology, India",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100558331","clinical-performance-of-medical-device-software-lipidica-10-for-processing-data-generated-by-lipidomic-analysis-in-pancreatic-cancer-screening-100558331","NCT06549725","Clinical Performance of Medical Device Software \"Lipidica 1.0\" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening","Inclusion Criteria Arm1:\n\n* Age ≥ 18 years\n* Signed informed consent\n* Histologically confirmed diagnosis of resectable PaC\n\nExclusion Criteria Arm 1:\n\n* History of any other cancer disease\n* Present incurable malignancy\n* Unfit for radical curative resection of the tumor\n* Vegan or vegetarian diet\n\nInclusion Criteria Arm2:\n\n* Age ≥ 18 years\n* Signed informed consent\n* High risk of PaC due to the presence of one of the following risk factors:\n\n  1. Family history of PaC (≥ 2 first-degree or second-degree relatives with PaC in the same family line)\n  2. Confirmed germline mutation of STK11 (LKB1) regardless of family history\n  3. Confirmed germline mutation of CDKN2A leading to the alteration of p16 regardless of family history\n  4. Confirmed germline mutation of APC, ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2 or TP53 AND ≥ 1 first-degree or second-degree relative with PaC\n  5. Present hereditary pancreatitis (recurrent acute pancreatitis or chronic pancreatitis and confirmed germline mutation of PRSS1)\n* Age:\n\n  1. Person with a family history of PaC: \\> 50 years or 10 years before the diagnosis of PaC in the youngest family member (whichever comes first)\n  2. Person with STK11 mutation: \\> 35 years or 10 years before the diagnosis of PaC in the youngest family member (whichever comes first)\n  3. Person with CDKN2A mutation: \\> 40 years or 10 years before the diagnosis of PaC in the youngest family member (whichever comes first)\n  4. Person with APC, ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2 or TP53 mutation: \\> 45 years or 10 years before the diagnosis of PaC in the youngest family member (whichever comes first)\n  5. Person with hereditary pancreatitis: \\> 40 years or 20 years after the 1st attack (whichever comes first)\n\nExclusion Criteria Arm 2:\n\n* Pregnancy of planning to conceive in the next 12 months\n* History of any cancer disease\n* Present incurable malignancy\n* Inability to undergo planned medical imaging or blood sampling\n* Vegan or vegetarian diet",true,{"count":89,"type":22},419,[91],"NA","Software \"Lipidica\" is intended to be used for processing data generated by the in-house in vitro diagnostic medical device for lipidomic testing for the purpose of screening Pancreatic cancer (PaC) in the population at high risk of this cancer due to familial risk, selected gene mutations or hereditary pancreatic diseases.\n\nThe primary objective is to verify that the investigational IVDSW can discriminate between results of patients with Pancreatic cancer and persons without Pancreatic cancer but at higher risk of this cancer disease due to their predispositions.\n\nParticipants will:\n\n* come to baseline and end of study visit for blood sampling and medical imaging\n* some participant will undertake one more visit depending on their results on baseline",[94,95,96,28],"Pancreas Cancer","Pancreatic Ductal Adenocarcinoma","Hereditary Diseases","2026-04-22",{"date":99,"type":41},"2026-04-27",{"date":101,"type":41},"2024-09-10",{"date":103,"type":22},"2027-09-26",{"name":105,"class":106},"Lipidica, a.s.","INDUSTRY",16,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100541482","pancreatic-cancer-screening-in-a-population-at-high-risk-100541482","NCT06330441","Pancreatic Cancer Screening in a Population at High Risk","ScrePan","Inclusion Criteria:\n\n* willing to participate in the study\n* age 18+\n* arms specific criteria:\n\nA:\n\n* chronic pancreatic disease in the context of cystic fibrosis or chronic pancreatitis\n* age 50+\n\nB1:\n\n* confirmed Peutz-Jegherson syndrome (mutSTK11) + age over 35 years or 10 years earlier than pancreatic ductal adenocarcinoma was diagnosed in the youngest family member\n* familial melanoma syndrome (mutCDKN2A) + age over 40 years or 10 years before pancreatic ductal adenocarcinoma was diagnosed in the youngest family member\n* confirmed hereditary pancreatitis (mutPRSS1) + age over 40 years or 20 years after the first attack\n\nB2:\n\n* confirmed diagnosis of hereditary syndrome (Lynch syndrome \u002FmutMLH1, mutMSH2, mutMSH6, mutPMS2, mutEPCAM\u002F, HBOC \u002FmutBRCA1, mutBRCA2, mutPALB2, mutATM\u002F, familial adenomatous polyposis \u002FmutAPC\u002F, Li-Fraumeni syndrome \u002FmutTP53\u002F)\n* at least one relative with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis at the same time (Grade I or II relative)\n* age over 50 years, or 10 years before the pancreatic ductal adenocarcinoma was diagnosed in the youngest relative - which comes first\n\nC:\n\n* positive family anamnesis of pancreatic ductal adenocarcinoma without hereditary syndrome context\n* age 50+ or 10 years earlier than the youngest relative with pancreatic ductal adenocarcinoma - screening is recommended for all first-degree relatives of affected family members\n\nExclusion Criteria:\n\n* Inability to undergo radical curative surgery for a pancreatic tumor.\n* Inability to undergo scheduled imaging examinations.\n* Incurable malignant cancer.",{"count":116,"type":22},700,[91],"Pancreatic cancer is one of the diseases with the worst prognosis, which is mainly due to the initial asymptomatic prognosis. Unfortunately, the incidence of this disease in the Czech Republic is still increasing. In a certain proportion of patients, it is possible to predict the disease, e.g. due to family burdens. Regular follow-up of such individuals is the subject of the SCREPAN study: \"Pancreatic Cancer Screening in High-Risk Persons\".",[95,96,28],[121,122,123],"pancreatic ductal adenocarcinoma","screening programme","high-risk population","2026-04-16",{"date":126,"type":41},"2026-04-21",{"date":128,"type":41},"2022-01-07",{"date":130,"type":22},"2028-01-06",{"name":132,"class":48},"Masaryk Memorial Cancer Institute",1,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100608515","indometacin-with-or-without-aggressive-intravenous-hydration-to-prevent-pancreatitis-after-pancreatic-extracorporeal-shock-wave-lithotripsy-100608515","NCT07202559","Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy","Aggressive Intravenous Hydration With Lactated Ringer's Solution Plus Rectal Indometacin Versus Rectal Indometacin Alone to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy: A Multicentre, Superiority, Randomised, Controlled Trial","Inclusion Criteria:\n\n* Patients with painful chronic pancreatitis eligible for P-ESWL treatment\n* Ages between 18-85 years\n* Providing informed consent\n\nExclusion Criteria:\n\n* Patients readmitted to the hospital for ESWL during the study period\n* contraindications to ESWL\n* Signs of congestive heart failure, such as pitting edema or a New York Heart Association classification greater than class I heart failure. For patients ≥ 70 years old, brain natriuretic peptide (BNP) and cardiac ultrasound would be performed before ESWL. Patients with BNP\\>100pg\u002Fml or Ejection Fraction value\\\u003C50% should be excluded\n* Respiratory insufficiency (pO2 \\\u003C 60 mmHg or saturation \\\u003C 90% despite FiO2 of 30% or requiring mechanical ventilation). For patients ≥ 70 years old, pulmonary function tests would be performed before ESWL. Patients with Forced Expiratory Volume in the first second (FEV1) \\\u003C70% are excluded\n* Patients receiving more than 1.5 mL\u002Fkg\u002Fh or 3 L\u002F24 h of intravenous fluids in the 24 h before ESWL\n* Hypotension (systolic blood pressure \\\u003C90 mmHg or mean arterial pressure \\\u003C70 mmHg)\n* Hypo- or hypernatremia (serum Na+ levels \\\u003C 130 or \\> 150 mmol\u002FL)\n* Severe liver disease (cirrhosis with ascites, liver abscess)\n* receiving NSAIDs within 7 days\n* Contraindications for rectal use of NSAIDs (renal dysfunction with serum creatinine \\>120 μmol\u002FL, allergy, active gastrointestinal bleeding, ulcer disease, and NSAID use for other indications \\[other than cardioprotective aspirin\\])\n* presence of coagulopathy or received anticoagulation therapy within 3 days\n* acute pancreatitis within 3 days\n* known active cardiovascular or cerebrovascular disease\n* pregnant or breastfeeding women\n* without a rectum (ie, status post-total proctocolectomy)","85 Years",{"count":143,"type":22},1250,[91],"This study aims to determine whether combining aggressive intravenous hydration with indometacin is more effective at preventing pancreatitis after a Extracorporeal Shock Wave Lithotripsy (ESWL) than using indometacin alone.\n\nThe study will involve patients who are scheduled to undergo ESWL for pancreatic stones. Participants will be randomly assigned to one of two groups: one will receive both the intravenous hydration and the rectal indometacin, while the other will receive only the rectal indometacin.\n\nThe trial will be conducted at multiple centers, ensuring a broad and diverse patient population.\n\nThe primary outcome of the study will be the incidence of pancreatitis after the ESWL procedure.\n\nThis study is important because it could lead to a better understanding of how to prevent pancreatitis after ESWL, potentially improving patient outcomes and reducing the risk of serious complications.",[28,29,147],"Pancreatic Duct Stones","2026-04-08",{"date":150,"type":41},"2026-04-13",{"date":152,"type":41},"2025-10-13",{"date":154,"type":22},"2027-12-01",{"name":156,"class":48},"Changhai Hospital",10,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":87,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":174,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":133},"100420906","intermittent-fasting-for-pancreatitis-100420906","NCT04760847","Intermittent Fasting for Pancreatitis","Intermittent Fasting as a Primary Means for Improving Quality of Life for Acute and Chronic Pancreatitis","IFPanc","Inclusion Criteria:\n\n* Age ≥ 18 year\n* Recurrent acute pancreatitis defined by greater than 2 episodes of pancreatitis, defined by:\n\nabdominal pain and either amylase or lipase \\> 3 x the upper limit of normal, imaging suggestive of, separated by time\n\n* Anatomy of chronic pancreatitis defined by Rosemont criterion9 or on imaging (CT, MRI)\n* Pancreatic exocrine insufficiency defined by a pancreatic elastase \\\u003C 200 ug\u002Fg stool10\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant Patients\n* Age \\> 80 years\n* Patients who cannot consent for themselves\n* Glycogen storage disease\n* Insulinoma or hypoglycemic state\n* Active alcohol abuse\n* Alcohol induced acute pancreatitis\n* Gallstone induced acute pancreatitis\n* Pancreatic solid neoplasm\n* Patients with diabetes\n* Patients on beta blockers",{"count":167,"type":22},64,[91],"The purpose of this research is to compare intermittent fasting with a standard diet approach for improving the quality of life related to your pancreas disease. Our hope is to improve your symptoms and prevent you from needing to go into the hospital for pancreas-related issues.",[171,29,28,172,173],"Pancreatitis","Pancreas Disease","Acute Recurrent Pancreatitis",[32,175,176,66,177,178],"acute pancreatitis","acute recurrent pancreatitis","fasting","intermittent fasting","2025-04-21",{"date":181,"type":41},"2025-04-22",{"date":183,"type":22},"2026-03",{"date":185,"type":22},"2026-04-01",{"name":187,"class":48},"H. Lee Moffitt Cancer Center and Research Institute"]